Department of Laboratory Medicine
University of Washington
 
Clinical assay interference and limitations

CK-MB [MBMASS, CPAIN, EPAIN, LPAIN]

Methodology: Abbott Axsym CK-MB immunoassay1

Interferences and limitations:

CK-MB levels can be increased in any condition resulting in myocardial cell damage. For diagnosis of acute myocardial infarction, CK-MB results should be used in conjunction with other information such as other cardiac markers (troponin), ECG, clinical observations and symptoms etc. Serial sampling is recommended to detect the temporal rise and fall of CK-MB levels characteristic of acute myocardial infarction.2

Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits which employ mouse monoclonal antibodies.3,4 These specimens should not be assayed for CK-MB using this assay. Please contact the Laboratory Medicine Resident on call 598-6190 if you need to have CK-MB measured in a patient that has received preparations of mouse monoclonal antibodies.

References:

1. Abbot Axsym CK-MB assay package insert, 7A57, 1999, Abbott Laboratories.

2. Keffer JH. The cardiac profile and proposed practice guideline for acute ischemic heart disease. Am J Clin Pathol 1997;107:859-860.

3. Schroff RW, Foon KA, Beatty SM, et al. Human anti-murine immunoglobulin responses in patients receiving murine monoclonal antibody therapy. Cancer Res 1985;45:879-885.

4. Primus FJ, Kelley EA, Hansen HJ, et al. "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988;34:261-264.



Please honor our copyrights and disclaimer.
Created: February 28, 2002
Copyright ©1999-2002 University of Washington. All rights reserved.
Update info to: "labmedhelp@u.washington.edu"